BOSTON, MA and SEATTLE, WA--(Marketwire - May 30, 2008) - Targeted Genetics Corporation (NASDAQ: TGEN) today announced additional interim data from its Phase 1/2 clinical study of tgAAC94 in patients with inflammatory arthritis. Pervin Anklesaria, PhD, Vice President of Therapeutic Development for Targeted Genetics, presented the data in an oral presentation at the 11th Annual Meeting of the American Society of Gene Therapy in Seattle (ASGT).
